Pallavi B. Limaye
University of Louisiana at Monroe
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Pallavi B. Limaye.
Toxicology and Applied Pharmacology | 2003
Pallavi B. Limaye; Udayan M. Apte; Kartik Shankar; Thomas J. Bucci; Alan Warbritton; Harihara M. Mehendale
Liver injury is known to progress even after the hepatotoxicant is long gone and the mechanisms of progressive injury are not understood. We tested the hypothesis that hydrolytic enzymes such as calpain, released from dying hepatocytes, destroy the surrounding cells causing progression of injury. Calpain inhibitor, N-CBZ-VAL-PHE-methyl ester (CBZ), administered 1 h after a toxic but nonlethal dose of CCl(4) (2 ml/kg, ip) to male Sprague Dawley rats substantially mitigated the progression of liver injury (6 to 48 h) and also led to 75% protection against CCl(4)-induced lethality following a lethal dose (LD75) of CCl(4) (3 ml/kg). Calpain leakage in plasma and in the perinecrotic areas increased until 48 h and decreased from 72 h onward paralleling progression and regression of liver injury, respectively, after CCl(4) treatment. Mitigation of progressive injury was accompanied by substantially low calpain in perinecrotic areas and in plasma after CBZ treatment. Normal hepatocytes incubated with the plasma collected from CCl(4)-treated rats (collected at 12 h when most of the CCl(4) is eliminated) resulted in extensive cell death prevented by CBZ. Cell-impermeable calpain inhibitor E64 also protected against progression of CCl(4)-induced liver injury, thereby confirming the role of released calpain in progression of liver injury. Following CCl(4) treatment, calpain-specific breakdown of alpha-fodrin increased, while it was negligible in rats receiving CBZ after CCl(4). Hepatocyte cell death in incubations containing calpain was completely prevented by CBZ. Eighty percent of Swiss Webster mice receiving a lethal dose (LD80) of acetaminophen (600 mg/kg, ip) survived if CBZ was administered 1 h after acetaminophen, suggesting that calpain-mediated progression of liver injury is neither species nor chemical specific. These findings suggest the role of calpain in progression of liver injury.
Hepatology | 2006
Pallavi B. Limaye; Vishakha S. Bhave; Prajakta S. Palkar; Udayan M. Apte; Sharmilee P. Sawant; Songtao Yu; John R. Latendresse; Janardan K. Reddy; Harihara M. Mehendale
Acute liver failure induced by hepatotoxic drugs results from rapid progression of injury. Substantial research has shown that timely liver regeneration can prevent progression of injury leading to a favorable prognosis. However, the mechanism by which compensatory regeneration prevents progression of injury is not known. We have recently reported that calpain released from necrotic hepatocytes mediates progression of liver injury even after the hepatotoxic drug is cleared from the body. By examining expression of calpastatin (CAST), an endogenous inhibitor of calpain in three liver cell division models known to be resistant to hepatotoxicity, we tested the hypothesis that increased CAST in the dividing hepatocytes affords resistance against progression of injury. Liver regeneration that follows CCl4‐induced liver injury, 70% partial hepatectomy, and postnatal liver development were used. In all three models, CAST was upregulated in the dividing/newly divided hepatocytes and declined to normal levels with the cessation of cell proliferation. To test whether CAST overexpression confers resistance against hepatotoxicity, CAST was overexpressed in the livers of normal SW mice using adenovirus before challenging them with acetaminophen (APAP) overdose. These mice exhibited markedly attenuated progression of liver injury and 57% survival. Whereas APAP‐bioactivating enzymes and covalent binding of the APAP‐derived reactive metabolites remained unaffected, degradation of calpain specific target substrates such as fodrin was significantly reduced in these mice. In conclusion, CAST overexpression could be used as a therapeutic strategy to prevent progression of liver injury where liver regeneration is severely hampered. (HEPATOLOGY 2006;44:379–388.)
Liver Regeneration#R##N#Basic Mechanisms, Relevant Models and Clinical Applications | 2015
Udayan Apte; Pallavi B. Limaye; George K. Michalopoulos
Abstract It is known that a large number of circulating extracellular signals including growth factors, cytokines, and other ligands mobilizing specific signaling pathways are involved in the stimulation of liver regeneration. Studies have shown that these extracellular signals vary to a great degree and details in their capacity to stimulate hepatocyte growth. Specialized assays using whole animals and hepatocyte cultures have been used to classify these signals in two categories, namely, primary or direct mitogens and secondary or auxiliary mitogens. This chapter will discuss the discovery of these mitogens, the endpoints used to determine their effect on hepatocyte proliferation, and in vivo evidence supporting the role of these mitogens.
Journal of Biological Chemistry | 2004
J. Christopher Corton; Udayan Apte; Steven P. Anderson; Pallavi B. Limaye; Lawrence Yoon; John R. Latendresse; Corrie Dunn; Jeffrey I. Everitt; Kenneth A. Voss; Cynthia Swanson; Carie L. Kimbrough; Jean S. Wong; Sarjeet S. Gill; Roshantha A. S. Chandraratna; Mi Kyoung Kwak; Thomas W. Kensler; Thomas M. Stulnig; Knut R. Steffensen; Jan Åke Gustafsson; Harihara M. Mehendale
Trends in Pharmacological Sciences | 2005
Harihara M. Mehendale; Pallavi B. Limaye
Journal of Pharmacology and Experimental Therapeutics | 2003
Sharmilee P. Sawant; Ankur V. Dnyanmote; Kartik Shankar; Pallavi B. Limaye; John R. Latendresse; Harihara M. Mehendale
Toxicological Sciences | 2002
Udayan Apte; Pallavi B. Limaye; Shashi K. Ramaiah; Vishal S. Vaidya; Thomas J. Bucci; Alan Warbritton; Harihara M. Mehendale
Toxicological Sciences | 2003
Udayan M. Apte; Pallavi B. Limaye; D. Desaiah; Thomas J. Bucci; Alan Warbritton; Harihara M. Mehendale
International Journal of Toxicology | 2001
Udayan M. Apte; Kartik Shankar; Vishal S. Vaidya; Pallavi B. Limaye
Hepatology | 2003
Pallavi B. Limaye; Udayan Apte; Prajakta S. Palkar; John C. Latendresse; Harihara M. Mehendale